• Sunitinib and Chrysin: Overcoming RCC Resistance via Ferropt

  2026-04-30

  Uncover how Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, and chrysin synergize to overcome resistance in renal cell carcinoma by inducing ferroptosis. This analysis delivers deeper mechanistic insights and actionable guidance for advanced RCC research.

• Mitoxantrone HCl: Applied DNA Topoisomerase II Inhibitor Wor

  2026-04-30

  Mitoxantrone HCl stands at the intersection of DNA damage research and nuclear receptor modulation, enabling advanced apoptosis and resistance studies in cancer and stem cell models. Discover optimized protocols, troubleshooting insights, and novel applications informed by recent mechanistic breakthroughs.

• Annexin V-Cy5/DAPI Apoptosis Kit: Mechanistic Precision in L

  2026-04-29

  Explore the Annexin V-Cy5/DAPI Apoptosis Kit as a next-generation apoptosis detection kit, with scientific insights bridging mitochondrial apoptosis mechanisms and advanced assay strategy. Discover unique guidance for leukemia and translational research.

• CP-673451: Selective PDGFRα/β Inhibitor for Advanced Cancer

  2026-04-29

  CP-673451 is a highly selective PDGFRα/β inhibitor that empowers researchers to dissect angiogenesis and tumor progression in preclinical models with unrivaled precision. Its proven efficacy in ATRX-deficient glioma and xenograft tumor models makes it a cornerstone for translational cancer research and biomarker-driven drug development.

• GLI2 Drives Tumor Immune Evasion via WNT and Prostaglandin P

  2026-04-28

  DeVito et al. elucidate how GLI2 coordinates WNT ligand and prostaglandin signaling to promote tumor immune evasion and resistance to anti-PD-1 immunotherapy. This mechanistic insight highlights GLI2 as a promising target for combinatorial strategies in cancer immunotherapy.

• Evaluating Drug Responses in Cancer: Refining In Vitro Metri

  2026-04-28

  Schwartz’s dissertation systematically evaluates how in vitro assays distinguish between anti-cancer drug effects on cell proliferation and cell death, revealing their distinct yet overlapping contributions to overall drug response. This clarification informs more precise experimental design and interpretation in preclinical cancer research.

• Jasplakinolide: Strategic Actin Modulation for Translational

  2026-04-27

  This thought-leadership article explores Jasplakinolide’s mechanisms as a potent actin polymerization inducer, integrating mechanistic insights, experimental validation, and translational considerations. Drawing on recent evidence—including chemical genetics approaches and benchmarking studies—this piece provides actionable guidance for translational researchers, highlights APExBIO’s Jasplakinolide as a premier actin cytoskeleton research tool, and advances the discussion beyond standard product summaries toward strategic implementation in next-generation biomedical research.

• Evaluating Fumagillin and Antiprotozoal Agents Against Azumi

  2026-04-27

  This study systematically assessed twenty candidate drugs for efficacy against Azumiobodo hoyamushi, the causative agent of soft tunic syndrome in edible ascidians. Fumagillin demonstrated moderate in vitro antiparasitic activity, offering insights for targeted interventions in aquaculture and informing broader research on methionine aminopeptidase-2 inhibitors.

• rTMS Promotes Cognitive Recovery in AD via GABAergic-Cx3cl1

  2026-04-26

  This study demonstrates that repetitive transcranial magnetic stimulation (rTMS) enhances cognitive recovery in Alzheimer's disease by activating GABAergic neurons, which upregulate the Cx3cl1-Cx3cr1 signaling axis. The findings reveal a mechanistic link between non-invasive neuromodulation and amyloid plaque clearance, highlighting new therapeutic targets and approaches for Alzheimer's disease intervention.

• Angiotensin III: Optimizing Cardiovascular and RAAS Assays

  2026-04-25

  Harnessing Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe) enables researchers to dissect AT1/AT2 signaling and aldosterone induction with precision. This guide provides advanced protocols, troubleshooting strategies, and a translation of cutting-edge literature for robust RAAS and cardiovascular research workflows.

• Ampicillin Sodium: Applied Workflows and Troubleshooting in

  2026-04-24

  Ampicillin sodium empowers precision in antibacterial activity assays and recombinant protein workflows, thanks to its robust β-lactam mechanism and high purity. This guide delivers stepwise protocols, advanced troubleshooting, and practical insights, enabling researchers to maximize reproducibility when studying bacterial cell wall biosynthesis inhibition.

• Partial BACE1 Inhibition Reduces Amyloid-β Without Synaptic

  2026-04-24

  Satir et al. (2020) demonstrate that partial inhibition of BACE1—achieving less than 50% reduction in amyloid-β secretion—can be accomplished without impairing synaptic transmission in neuronal cultures. This finding reshapes the risk-benefit balance for BACE1 inhibitor dosing strategies in Alzheimer's disease research and highlights a threshold for safer therapeutic intervention.

• Partial BACE1 Inhibition Reduces Amyloid Beta Without Impair

  2026-04-23

  Satir et al. (2020) demonstrate that partial inhibition of BACE1 can decrease amyloid beta production by up to 50% without disrupting synaptic transmission in primary neurons. This finding revises the risk profile for BACE inhibitors in Alzheimer's disease research, suggesting moderate reduction strategies may preserve neuronal function.

• Notch Inhibition Boosts Immunotherapy in Triple-Negative Bre

  2026-04-23

  This study demonstrates that pharmacological inhibition of the Notch signaling pathway enhances the efficacy of immune checkpoint blockade (ICB) in triple-negative breast cancer (TNBC) by reshaping the tumor immune microenvironment. The findings highlight a new combinatorial approach to overcoming immunotherapy resistance in aggressive breast cancer subtypes.

• Amyloid Beta-peptide (25-35): Applied Neurotoxicity Models &

  2026-04-22

  Amyloid Beta-peptide (25-35) (Aβ25-35) is a gold-standard model for dissecting Alzheimer’s disease neurotoxicity and microglial polarization. Here, we translate the latest mechanistic insights and troubleshooting strategies into actionable workflows for robust, reproducible neurodegenerative disease research.

16150 records 1/1077 page Next 12345 下5页 Last page